Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 07, 2026
Why Is Xponential Fitness (XPOF) Stock Down -25.31% Today?

Why Is Xponential Fitness (XPOF) Stock Down -25.31% Today?

Key Takeaways

  • Xponential Fitness shares plunged approximately 25.31% to $4.75 during Friday's regular trading session, following a disastrous Q2 2026 earnings report released after the close on August 6.
  • The primary catalyst was a severe earnings miss: adjusted EPS of $0.02 fell 84.9% short of the $0.13 analyst consensus, while full-year revenue and EBITDA guidance were slashed well below Wall Street expectations.
  • Same-store sales declined 6.8% across North America, with flagship brand Club Pilates posting a 5% drop, signaling weakening consumer demand across the boutique fitness franchisor's portfolio.
  • Guggenheim downgraded the stock to Neutral on August 7, adding further selling pressure to an already battered share price.
  • Volume surged dramatically above average, reflecting capitulation-style selling as investors reassessed the company's growth trajectory and profitability outlook.
  • Traders are now watching for any stabilization signals, potential further analyst downgrades, and management's ability to execute on turnaround initiatives under CEO Mike Nuzzo.

Opening Summary

XPOF, the parent company of boutique fitness brands including Club Pilates, StretchLab, YogaSix, Pure Barre, and BFT, saw its shares crater roughly 25.31% to $4.75 in intraday trading on Friday, August 7, 2026. The collapse follows the company's second-quarter 2026 earnings release, which closed at $6.36 on August 6 and revealed an adjusted profit of just $0.02 per share — a dramatic 84.9% miss versus the $0.13 consensus — along with sharply reduced full-year guidance across revenue, EBITDA, and new studio openings. The selloff, which began in after-hours trading with a 12.7% drop, accelerated during the regular session as the market fully digested the magnitude of the guidance cut and a Guggenheim downgrade.

Q2 Earnings Miss and Slashed Guidance

Xponential Fitness reported Q2 revenue of $65.97 million, edging past the $64.39 million consensus estimate but still representing a 13.4% year-over-year decline. The revenue beat, however, was completely overshadowed by the bottom-line catastrophe. Adjusted EBITDA of $21.94 million missed analyst projections of $26.29 million by 16.6%, while operating margin contracted to 14.4% from 19.5% a year ago. Free cash flow margin nearly evaporated at just 0.1%.

Perhaps most alarming was the company's revised 2026 outlook. Management now expects full-year revenue of $250 million to $260 million, down from prior guidance of $260 million to $270 million and below the $263.9 million consensus. Adjusted EBITDA guidance was slashed to $91 million to $97 million from $100 million to $110 million. New studio openings were cut to approximately 150 from the previous 150–170 range. North America system-wide sales guidance of $1.70 billion to $1.75 billion also fell below prior forecasts.

Same-Store Sales Weakness Signals Deeper Consumer Headwinds

Underlying the disappointing results was a 6.8% decline in North America same-store sales — a critical metric for any franchise-based business. Club Pilates, the company's largest and most important brand with over 1,500 studios, posted a 5% same-store sales decline. This deterioration suggests that the boutique fitness consumer is pulling back on discretionary spending, potentially reflecting broader macroeconomic pressure on middle-to-upper-income households that form Xponential's core demographic. The company attributed part of the decline to brand divestitures completed in 2025, including the sales of CycleBar, Rumble, and Lindora, but the magnitude of the drop points to organic weakness as well.

Analyst Downgrade Compounds Selling Pressure

Adding fuel to the fire, Guggenheim downgraded XPOF to a Neutral rating on August 7, removing what had been a bullish endorsement from a notable sell-side firm. The downgrade amplified negative sentiment and likely triggered additional institutional selling, as portfolio managers who rely on sell-side ratings reassessed their positions. The downgrade reflects growing concern that Xponential's path to sustained profitable growth may be longer and more uncertain than previously anticipated.

Market Context and Trading Activity

Trading volume during Friday's session was extraordinarily elevated, running multiples above the stock's average daily volume of approximately 670,000 shares. The prior session on August 6 had already seen volume of roughly 1.33 million shares as some investors anticipated the earnings report, dwarfing the prior four sessions which averaged well under 600,000 shares. The selloff in XPOF was largely company-specific, as broader market indices did not exhibit comparable declines, confirming that the catalyst was overwhelmingly the earnings disappointment rather than a macro-driven rout. The stock broke decisively below its recent trading range in the $6.00–$7.00 zone and is now approaching its 52-week low of $3.83 set in early March 2026.

What Comes Next for XPOF

Looking ahead, investors will be closely monitoring whether the newly appointed leadership team under CEO Mike Nuzzo can stabilize the business. The company has outlined strategic initiatives including a transition to a new national marketing agency, CRM automation, modest inflationary price adjustments, and a studio refresh program. However, execution risks remain substantial. The reduction in planned studio openings to roughly 150 from 201 in 2025 signals that franchisee economics may be deteriorating, potentially leading to further closures beyond the 3%–5% rate management has forecast. With $522.8 million in total debt against just $21.5 million in cash as of Q1, the balance sheet remains highly leveraged. Any further deterioration in same-store sales or franchisee health could put additional pressure on the stock. The company's next quarterly report will be critical in determining whether the Q2 results represent a temporary setback or the beginning of a more sustained downturn.

Trending AI Robots

In volatile market environments like the one currently impacting XPOF, traders increasingly turn to data-driven tools for timely decision-making. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated strong performance under prevailing market conditions. With hundreds of bots covering thousands of tickers across diverse strategies, timeframes, and performance metrics, this resource helps traders identify which algorithmic approaches are currently beating the market. Explore the Trending AI Robots page to see which strategies are generating signals aligned with today's market dynamics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XPOF

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


XPOF in upward trend: price may ascend as a result of having broken its lower Bollinger Band on August 07, 2026

XPOF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where XPOF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for XPOF's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XPOF advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where XPOF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XPOF as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XPOF turned negative on August 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

XPOF moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XPOF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XPOF entered a downward trend on August 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XPOF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (3.655). P/E Ratio (26.609) is within average values for comparable stocks, (49.914). XPOF's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.233). XPOF's Dividend Yield (0.000) is considerably lower than the industry average of (0.024). P/S Ratio (0.653) is also within normal values, averaging (5.679).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XPOF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are YETI Holdings (NYSE:YETI), Peloton Interactive (NASDAQ:PTON).

Industry description

The Leisure and Recreation Products industry includes companies offering recreational goods/services such as video games, swimming pools, golf courses, boats, outdoor spaces etc. Since these are mainly geared towards consumers, strong employment conditions and healthy incomes generally augur well for the recreational products industry. Some of the largest market caps in this space belong to video game developers (e.g. Activision Blizzard, Electronic Arts and Take-two Interactive), and toy /board game makers (like Hasbro).

Market Cap

The average market capitalization across the Recreational Products Industry is 2.44B. The market cap for tickers in the group ranges from 5.94K to 27.43B. ANPDF holds the highest valuation in this group at 27.43B. The lowest valued company is CLUBQ at 5.94K.

High and low price notable news

The average weekly price growth across all stocks in the Recreational Products Industry was 2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was -5%. KMRK experienced the highest price growth at 25%, while TRUG experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Recreational Products Industry was 128%. For the same stocks of the Industry, the average monthly volume growth was 130% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 66
Price Growth Rating: 61
SMR Rating: 70
Profit Risk Rating: 92
Seasonality Score: -39 (-100 ... +100)
View a ticker or compare two or three
XPOF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry RecreationalProducts

Profile
Details
Industry
N/A
Address
17877 Von Karman Avenue
Phone
+1 949 346-3000
Employees
690
Web
https://www.xponential.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.